Navigation Links
Researchers develop gene therapy that could correct a common form of blindness
Date:1/23/2012

where they were needed, and not to any other places in the body. The study gave a good approximation of how the gene therapy might work in humans.

"The results are encouraging and the rescue of the damaged photoreceptor cells is quite convincing," said Flannery, who is on the scientific advisory board of the Foundation Fighting Blindness, which provided some funding for the study. "Since this type of study is often the step before applying a treatment to human patients, showing that it works is critical."

The researchers plan to repeat their studies on a larger scale over a longer term, and make a version of the virus that proves to be safe in humans. Once that is achieved, a pharmaceutical grade of the virus would have to be produced and tested before moving into clinical trials in humans. The researchers will be able to use much of the technology they have already developed and used successfully to restore vision.


'/>"/>
Contact: Czerne M. Reid
czerne@ufl.edu
352-273-5814
University of Florida
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers meet to refine carbon budget for US East Coast
2. Penn researchers help solve questions about Ethiopians high-altitude adaptations
3. Notre Dame researchers report fundamental malaria discovery
4. Researchers find gene critical to sense of smell in fruit fly
5. Native forest birds in unprecedented trouble, according to University of Hawaii at Manoa researchers
6. Researchers discover green pesticide for citrus pests
7. 2-timing and hybrids: RUB researchers look back on 100 million years of evolution
8. Researchers identify possible receptor for key breast cancer regulator
9. UH Manoa researchers discover novel chemical route to form organic molecules
10. Researchers: Honeybee deaths linked to seed insecticide exposure
11. Worm seeks worm: Caltech researchers find chemical cues driving aggregation in nematodes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Change: Required Reductions of Carbon Emissions to Protect Young ... colleagues, and announces call for papers on responses to ... impacts of global warming using ongoing observations and paleoclimate ... representations of the global carbon cycle and temperature to ...
... EVENT: The second annual Epigenetic Control and ... and chromatin remodeling contribute to various processes that lead ... Friday, Dec. 12-13, at the At the Beckman Center ... Irvine, Calif. INFORMATION: Media planning to ...
... to sustaining life on Earth, is proving deadly for young peregrine ... in Oecologia has found that an increase in the ... posing a threat not seen in this species since before pesticides ... , The study is among the first to directly link rainfall ...
Cached Biology News:Assessing dangerous climate change and call for climate change response papers 2Top scientists to present at Epigenetic Control and Cellular Plasticity symposium 2Rainfall to blame for decline in Arctic peregrines 2
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and ... the Huntsworth Health Group, is proud to announce the ... her role, Gonzales will serve as Senior Vice President ... to welcome a talent of Jamie’s caliber to the ... “She is a proven healthcare innovation leader and brand ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... high-tech networking event starting in Appleton, Wisconsin. The ... investors and others who live in the Fox ... Tobey Andropolis and Bob Pankratz insist that this ... enterprise. Instead, the Hive is devoted to helping ...
... 2004 in Lille, France. This four-year-old conference draws ... transformative power of technology. As the lead speaker on ... and Social Conditions, I was eager, frankly, to dispense ... to hear from and debate my fellow panelists. , ...
... scientists have research on the brain. In the past few ... effort into projects that can combat neural disorders and help ... area of human testing and getting closer to market, their ... Implants encourage mind over movement ,One major effort at ...
Cached Biology Technology:A new high-tech networking event buzzes in Appleton 2A new high-tech networking event buzzes in Appleton 3Achieving digital solidarity 2Achieving digital solidarity 3Achieving digital solidarity 4Mental research at UW-Madison could correct disabilities 2Mental research at UW-Madison could correct disabilities 3
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
...
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Biology Products: